Advertisement
Singapore markets open in 2 hours
  • Straits Times Index

    3,296.89
    +4.20 (+0.13%)
     
  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     
  • Dow

    38,225.66
    +322.37 (+0.85%)
     
  • Nasdaq

    15,840.96
    +235.48 (+1.51%)
     
  • Bitcoin USD

    59,389.22
    +1,581.51 (+2.74%)
     
  • CMC Crypto 200

    1,277.17
    +6.43 (+0.51%)
     
  • FTSE 100

    8,172.15
    +50.91 (+0.63%)
     
  • Gold

    2,313.00
    +3.40 (+0.15%)
     
  • Crude Oil

    79.16
    +0.21 (+0.27%)
     
  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     
  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     
  • Hang Seng

    18,207.13
    +444.10 (+2.50%)
     
  • FTSE Bursa Malaysia

    1,580.30
    +4.33 (+0.27%)
     
  • Jakarta Composite Index

    7,117.42
    -7,234.20 (-50.41%)
     
  • PSE Index

    6,646.55
    -53.94 (-0.81%)
     

Elevance Health First Quarter 2024 Earnings: EPS Misses Expectations

Elevance Health (NYSE:ELV) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$42.6b (up 1.0% from 1Q 2023).

  • Net income: US$2.25b (up 13% from 1Q 2023).

  • Profit margin: 5.3% (up from 4.7% in 1Q 2023).

  • EPS: US$9.59 (up from US$8.38 in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Elevance Health EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%.

Looking ahead, revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US.

ADVERTISEMENT

Performance of the American Healthcare industry.

The company's shares are up 4.6% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Elevance Health that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.